PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report

RATIONALE: Routine neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma prior to radical surgery is curative. With the increase in cancer immunotherapy, neoadjuvant immunotherapy has been used as an important complement to neoadjuvant chemotherapy for muscle-invasive urothelial carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Huaqi, Yongkang, Ma, Bao, Guan, Shiming, Zhao, Chaohong, He, Tiejun, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757928/
https://www.ncbi.nlm.nih.gov/pubmed/35029241
http://dx.doi.org/10.1097/MD.0000000000028591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757928/
https://www.ncbi.nlm.nih.gov/pubmed/35029241
http://dx.doi.org/10.1097/MD.0000000000028591

Ejemplares similares